With nearly $14 billion sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk (NOVOb.CO), opens new tab, whose profits from blockbuster weight-loss drug Wegovy propelled it to become Europe's most ...

Analyst Michael Nedelcovych from TD Cowen maintained a Buy rating on Novo Nordisk (NVO – Research Report) and keeping the price target at $155.00. Michael Nedelcovych has given his Buy rating ...

Novo Nordisk A/S (NVO)’s share was trading at $109.09 as of Nov 11th. NVO’s trailing and forward P/E were 35.82 and 27.70 respectively according to Yahoo Finance. Novo […] ...

Bagsværd, Denmark, 8 November 2024 - Today, Novo Nordisk A/S has entered into an agreement to purchase 6,311,250 B shares of DKK 0.10 at a value of DKK 4,736,088,225.00 from Novo Holdings A/S. The ...

Eli Lilly and Novo Nordisk didn't quite beat expectations with their recent earnings. Their weight loss drugs slightly underperformed. That underperformance may portend more difficulty.

Halozyme makes 2 billion euro buyout offer for drug developer Evotec November 14, 2024 Novo Nordisk is gradually ending production of human insulin pens, the drugmaker told Reuters, as it spends ...

Novo Nordisk has taken the bold step of buying three manufacturing facilities from contract development and manufacturing organisation Catalent as it tries to meet surging demand for its diabetes ...

Novo Nordisk is planning to open an artificial intelligence (AI) research facility in London, UK, as part of a drive to place the technology at the heart of its drug discovery operations.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...